Table 2.

Differentiating metabolites and pathways in the control and treated P. falciparum with IC₅₀ dose of CQ and NDC-CQ

No.	Metabolic pathways	NDC-CQ/CQ	Total	Expected	Hits	Raw P	Impact
1	Glyoxylate and dicarboxylate metabolism	+/+	12	0.27	2	2.62 × 10−2	0.50
2	Nitrogen metabolism	+/-	3	0.07	1	6.55 × 10−2	0.00
3	Riboflavin metabolism	+/-	3	0.07	1	6.55 × 10−2	1.00
4	Aminoacyl-tRNA biosynthesis	+/-	46	1.02	3	7.23 × 10−2	0.00
5	Glutathione metabolism	+/+	21	0.47	2	7.48 × 10−2	0.39
6	Phenylalanine, tyrosine and tryptophan biosynthesis	+/-	6	0.13	1	1.27 × 10−1	0.01
7	Thiamine metabolism	+/+	11	0.24	1	2.22 × 10−1	0.02
8	Alanine, aspartate and glutamate metabolism	+/-	12	0.27	1	2.39 × 10−1	0.26
9	Cysteine and methionine metabolism	+/-	14	0.31	1	2.74 × 10−1	0.00
10	Arginine and proline metabolism	+/-	17	0.38	1	3.23 × 10−1	0.00
11	Citrate cycle (TCA cycle)	+/+	20	0.45	1	3.69 × 10−1	0.13
12	Pyrimidine metabolism	+/-	31	0.69	1	5.15 × 10−1	0.03
13	Terpenoid backbone biosynthesis	-/+	15	0.20	1	1.85 × 10−1	0.00
14	Pyruvate metabolism	-/+	20	0.27	1	2.40 × 10−1	0.15
15	Glycolysis or Gluconeogenesis	-/+	23	0.31	1	2.72 × 10−1	0.10

Total, total number of compounds in the pathway; Hits, the actual matched number from data uploaded by user; Raw P, the P value derived from enrichment analysis; Holm P, the P value adjusted using Holm–Bonferroni method; FDR P, the P value adjusted using false discovery rate; Impact, the pathway impact value derived by pathway topology analysis.

The table above incorporates the detailed results from pathway analysis. The statistical P values from enrichment analysis are further adjusted for multiple testing to accommodate for many pathways that are tested simultaneously.